YU.V. GARIFULLOVA², L.I. MALTSEVA¹, M.G. KALINKINA³

¹Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

²Kazan State Medical University, Kazan

³Republic Clinical Oncology Dispensary, Kazan

Contact details:

Garifullova Y.V. — PhD (medicine), Assistant Lecturer of the Department of Obstetrics and gynecology named after V.S. Gruzdev

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-919-637-22-33, e-mail: gamil.garifullov@yandex.ru

High density of the mammary gland, determined with the digital mammography method, is an independent risk factor for mammary gland cancer (MGC). Prescription of combined oral contraceptives, menopausal hormone therapy drugs, intrauterine system with levonorgestrel, and ovulation induction may lead to an increase of mammary gland density (MGD). The latest research showed that the insulin-like growth factor is also a risk factor for mammary gland density. In the Republic of Tatarstan, out of 265,217 examined women, a high mammary gland density was diagnosed in 7%, including in patients older than 60 y. o. Notably, in the overwhelming majority of them the density did not decrease during 3 years of monitoring. This testifies to the need of prolonged monitoring of mammary glands in patients, combined with estimation and correction of risk factors for mammary gland density.

Key words: mammography, mammary gland density, mammary gland cancer.

REFERENCES

1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, May, vol. 71 (3), pp. 209–249.
2. Kogan I.Yu. Mastopathy: new approaches to diagnosis and pathogenetic therapy. Zhurnal akusherstva i zhenskikh bolezney, 2010, vol. LIX, iss. 1, pp. 66–70 (in Russ.).
3. Mal’tseva L.I., Garifullova Yu.V. The possibilities of ultrasound examination of the mammary glands in assessing the effectiveness of the treatment of diffuse mastopathy with vitamin D. Prakticheskaya meditsina, 2022, vol. 20, no. 1, pp. 74–79 (in Russ.).
4. Morch L.S., Skovlund C.W., Hannaford P.C. et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med, 2017, vol. 377 (23), pp. 2228–2239.
5. Brinton L.A., Scoccia B., Moghissi K.S. et al. Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev, 2014, vol. 23 (4), pp. 584–593.
6. Beral V., Reeves G., Bull D. et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst, 2011, vol. 103 (4), pp. 296–305.
7. Iversen L., Sivasubramaniam S., Lee A.J. et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol, 2017, vol. 216, pp. 580.e1–580.9e.
8. Klinicheskie rekomendatsii MZ RF «Dobrokachestvennaya displaziya molochnoy zhelezy» (Utv. MZ RF), 2020 [Clinical guidelines of the Ministry of Health of the Russian Federation «Benign breast dysplasia» (Approved by the Ministry of Health of the Russian Federation), 2020].
9. Tabar L., Dean P.B., Chen T.H. et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer, 2019, vol. 125 (4), pp. 515–523.
10. Garifullova, Yu.V. Radiation methods for diagnosing benign diseases of the mammary glands. Prakticheskaya meditsina, 2017, no. 7 (108), pp. 51‒56 (in Russ.).
11. Fisher U. Mammografiya: 100 klinicheskikh sluchaev [Mammography: 100 clinical cases]. Moscow: MEDpress-inform, 2009. 368 p.
12. Mainiero M.B., Lourenco A., Maboney M.C. et al. ACR appropriateness criteria for breast cancer screening. J. Am. Coll. Radiol, 2013, vol. 10, pp. 11–14.
13. Berg W.A., Zhang Zh., Lehrer D. et al. Detection of Breast Cancer with Addition of Annual Screening Ultrasound or a Single Screening MRI to Mammography in Women with Elevated Breast Cancer Risk. JAMA, 2012, vol. 307 (13), pp. 1394–1404. DOI: 10.1001/jama.2012.388
14. Sasaki J., Geletzke A., Kass R.B., Klimberg V.S., Copeland E.M., Bland K.I. (2018). Etiology and management of benign breast disease. In The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc., 2018. Pp. 79–92.e5. DOI: 10.1016/B978-0-323-35955-9.00005-2
15. De Bel T., Litiens G., Ogony J. et al. Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning. NPJ Breast Cancer, 2022, vol. 8 (1), p. 13.
16. Kim H., Moon W.K. Histological Findings of Mammary Gland Development and Risk of Breast Cancer in BRCA1 Mutant Mouse Models. J Breast Cancer, 2021, vol. 24 (5), pp. 455–462. Epub 2021 Oct 5.
17. Sung H., Guo C., Li E. et al. The relationship between terminal duct lobular unit features and mammographic density among Chinese breast cancer patients. Int J Cancer, 2019, vol. 145 (1), pp. 70–77. DOI: 10.1002/ijc.32077 Epub 2019 Jan 7.
18. Horne H.N., Sherman M.E, Pfeiffer R.M. et al. Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Res, 2016, vol. 18 (1), p. 24. DOI: 10.1186/s13058-016-0678-4
19. Oh H., Pfeiffer R.M., Falk R.T. et al. Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank. Int J Cancer, 2018, vol. 143 (3), pp. 496–507.